Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
ALGN's Cash-to-Debt is ranked higher than
99% of the 330 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. ALGN: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ALGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 5.57  Med: No Debt Max: No Debt
Current: No Debt
5.57
No Debt
Equity-to-Asset 0.64
ALGN's Equity-to-Asset is ranked higher than
54% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. ALGN: 0.64 )
Ranked among companies with meaningful Equity-to-Asset only.
ALGN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.55  Med: 0.74 Max: 0.89
Current: 0.64
0.55
0.89
Interest Coverage No Debt
ALGN's Interest Coverage is ranked higher than
99% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: 66.37 vs. ALGN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ALGN' s Interest Coverage Range Over the Past 10 Years
Min: 39.17  Med: 150.26 Max: No Debt
Current: No Debt
39.17
No Debt
Piotroski F-Score: 7
Altman Z-Score: 24.06
Beneish M-Score: -2.84
WACC vs ROIC
13.85%
62.57%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 24.76
ALGN's Operating Margin % is ranked higher than
90% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.96 vs. ALGN: 24.76 )
Ranked among companies with meaningful Operating Margin % only.
ALGN' s Operating Margin % Range Over the Past 10 Years
Min: -10.47  Med: 22.68 Max: 27.71
Current: 24.76
-10.47
27.71
Net Margin % 17.00
ALGN's Net Margin % is ranked higher than
86% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. ALGN: 17.00 )
Ranked among companies with meaningful Net Margin % only.
ALGN' s Net Margin % Range Over the Past 10 Years
Min: -10.01  Med: 16.37 Max: 26.31
Current: 17
-10.01
26.31
ROE % 25.60
ALGN's ROE % is ranked higher than
92% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. ALGN: 25.60 )
Ranked among companies with meaningful ROE % only.
ALGN' s ROE % Range Over the Past 10 Years
Min: -12.72  Med: 19.29 Max: 42.13
Current: 25.6
-12.72
42.13
ROA % 16.89
ALGN's ROA % is ranked higher than
92% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: -0.26 vs. ALGN: 16.89 )
Ranked among companies with meaningful ROA % only.
ALGN' s ROA % Range Over the Past 10 Years
Min: -9.86  Med: 14 Max: 31.86
Current: 16.89
-9.86
31.86
ROC (Joel Greenblatt) % 122.74
ALGN's ROC (Joel Greenblatt) % is ranked higher than
97% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 3.87 vs. ALGN: 122.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ALGN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -114.37  Med: 174.76 Max: 385.53
Current: 122.74
-114.37
385.53
3-Year Revenue Growth Rate 24.80
ALGN's 3-Year Revenue Growth Rate is ranked higher than
90% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. ALGN: 24.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ALGN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 7.6  Med: 15.55 Max: 146.7
Current: 24.8
7.6
146.7
3-Year EBITDA Growth Rate 23.00
ALGN's 3-Year EBITDA Growth Rate is ranked higher than
70% of the 232 Companies
in the Global Medical Devices industry.

( Industry Median: 7.50 vs. ALGN: 23.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ALGN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 15.2 Max: 45.2
Current: 23
0
45.2
3-Year EPS without NRI Growth Rate 16.90
ALGN's 3-Year EPS without NRI Growth Rate is ranked higher than
63% of the 223 Companies
in the Global Medical Devices industry.

( Industry Median: 7.80 vs. ALGN: 16.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ALGN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 20.4 Max: 289.3
Current: 16.9
0
289.3
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ALGN's 30-Y Financials

Financials (Next Earnings Date: 2018-10-26)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

ALGN Guru Trades in Q3 2017

Andreas Halvorsen 581,967 sh (New)
Jim Simons 2,037,200 sh (+28.31%)
Lee Ainslie 18,610 sh (+15.30%)
Ron Baron 116,493 sh (+9.23%)
Ruane Cunniff Sold Out
Caxton Associates Sold Out
Mariko Gordon 23,667 sh (-0.53%)
Pioneer Investments 218,657 sh (-0.70%)
Ken Fisher 91,526 sh (-5.09%)
Columbia Wanger 637,971 sh (-15.56%)
Mario Gabelli 1,500 sh (-16.67%)
» More
Q4 2017

ALGN Guru Trades in Q4 2017

Caxton Associates 3,560 sh (New)
Joel Greenblatt 5,326 sh (New)
Lee Ainslie 25,650 sh (+37.83%)
Jim Simons 2,614,100 sh (+28.32%)
Ron Baron 116,493 sh (unchged)
Ken Fisher 88,524 sh (-3.28%)
Pioneer Investments 207,444 sh (-5.13%)
Andreas Halvorsen 542,532 sh (-6.78%)
Mariko Gordon 19,099 sh (-19.30%)
Mario Gabelli 1,200 sh (-20.00%)
Columbia Wanger 268,648 sh (-57.89%)
» More
Q1 2018

ALGN Guru Trades in Q1 2018

Frank Sands 2,709,813 sh (New)
Ray Dalio 3,881 sh (New)
Paul Tudor Jones 1,360 sh (New)
Mario Gabelli 3,200 sh (+166.67%)
Lee Ainslie 32,410 sh (+26.35%)
Jim Simons 2,958,600 sh (+13.18%)
Andreas Halvorsen Sold Out
Joel Greenblatt Sold Out
Ron Baron 116,483 sh (-0.01%)
Caxton Associates 3,397 sh (-4.58%)
Ken Fisher 70,134 sh (-20.77%)
Pioneer Investments 159,860 sh (-22.94%)
Mariko Gordon 10,259 sh (-46.29%)
» More
Q2 2018

ALGN Guru Trades in Q2 2018

Pioneer Investments 262,544 sh (+64.23%)
Ron Baron 161,653 sh (+38.78%)
Frank Sands 3,059,358 sh (+12.90%)
Mariko Gordon 10,061 sh (-1.93%)
Jim Simons 2,894,800 sh (-2.16%)
Ken Fisher 65,036 sh (-7.27%)
Mario Gabelli 2,590 sh (-19.06%)
Caxton Associates 2,405 sh (-29.20%)
Lee Ainslie 20,590 sh (-36.47%)
Paul Tudor Jones 759 sh (-44.19%)
Ray Dalio 1,665 sh (-57.10%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ALGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2018-06-30 Add 38.78%0.07%$239.66 - $370.1 $ 311.695%161,653
Ken Fisher 2018-06-30 Reduce -7.27%$239.66 - $370.1 $ 311.695%65,036
Mariko Gordon 2018-06-30 Reduce -1.93%$239.66 - $370.1 $ 311.695%10,061
Mario Gabelli 2018-06-30 Reduce -19.06%$239.66 - $370.1 $ 311.695%2,590
Ron Baron 2018-03-31 Reduce -0.01%$220.71 - $283.97 $ 311.6921%116,483
Ken Fisher 2018-03-31 Reduce -20.77%0.01%$220.71 - $283.97 $ 311.6921%70,134
Mariko Gordon 2018-03-31 Reduce -46.29%0.12%$220.71 - $283.97 $ 311.6921%10,259
Mario Gabelli 2018-03-31 Add 166.67%0.01%$220.71 - $283.97 $ 311.6921%3,200
Joel Greenblatt 2018-03-31 Sold Out 0.02%$220.71 - $283.97 $ 311.6921%0
Ken Fisher 2017-12-31 Reduce -3.28%$185.98 - $264.23 $ 311.6938%88,524
Mariko Gordon 2017-12-31 Reduce -19.30%0.05%$185.98 - $264.23 $ 311.6938%19,099
Joel Greenblatt 2017-12-31 New Buy0.02%$185.98 - $264.23 $ 311.6938%5,326
Mario Gabelli 2017-12-31 Reduce -20.00%$185.98 - $264.23 $ 311.6938%1,200
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3842
Compare:NYSE:ZBH, LSE:SN., NYSE:EW, NAS:ABMD, NYSE:TFX, XSWX:SOON, NYSE:VAR, SZSE:300003, OCSE:WDH, XPAR:DIM, ASX:COH, LSE:CTEC, NZSE:FPH, NYSE:GMED, OCSE:AMBU B, NAS:IART, OCSE:GN, NAS:MASI, OSTO:EKTA B, NYSE:PEN » details
Traded in other countries:AFW.Germany,
Headquarter Location:USA
Align Technology Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM digital services used in dentistry, orthodontics, and dental records storage. Its segments are Clear Aligner and Scanners & Services.

Align Technology Inc provides a clear aligner therapy system, intra-oral scanners, and computer-aided design/computer-aided manufacture digital services used in dentistry and orthodontics. The firm operates in two segments: Clear Aligner and scanners and services. The Clear Aligner segment generates the vast majority of revenue and sells the Invisalign System, which uses clear plastic removable orthodontic aligners to treat misaligned teeth. This segment also sells retainers. The scanners and services segment's key product is the iTero Scanner, an intra-oral scanner that can be used with Invisalign treatment. The iTero platform also can be used with software for restorative or orthodontic procedures. Align receives the majority of its revenue from the United States.

Ratios

vs
industry
vs
history
PE Ratio 86.59
ALGN's PE Ratio is ranked lower than
89% of the 180 Companies
in the Global Medical Devices industry.

( Industry Median: 30.17 vs. ALGN: 86.59 )
Ranked among companies with meaningful PE Ratio only.
ALGN' s PE Ratio Range Over the Past 10 Years
Min: 5.57  Med: 34.5 Max: 222.88
Current: 86.59
5.57
222.88
Forward PE Ratio 49.51
ALGN's Forward PE Ratio is ranked lower than
92% of the 52 Companies
in the Global Medical Devices industry.

( Industry Median: 25.06 vs. ALGN: 49.51 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 86.59
ALGN's PE Ratio without NRI is ranked lower than
91% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 30.17 vs. ALGN: 86.59 )
Ranked among companies with meaningful PE Ratio without NRI only.
ALGN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.57  Med: 34.5 Max: 222.88
Current: 86.59
5.57
222.88
Price-to-Owner-Earnings 75.47
ALGN's Price-to-Owner-Earnings is ranked lower than
77% of the 104 Companies
in the Global Medical Devices industry.

( Industry Median: 32.03 vs. ALGN: 75.47 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ALGN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.35  Med: 35.44 Max: 895
Current: 75.47
5.35
895
PB Ratio 20.54
ALGN's PB Ratio is ranked lower than
94% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. ALGN: 20.54 )
Ranked among companies with meaningful PB Ratio only.
ALGN' s PB Ratio Range Over the Past 10 Years
Min: 1.86  Med: 5.51 Max: 25.78
Current: 20.54
1.86
25.78
PS Ratio 14.68
ALGN's PS Ratio is ranked lower than
86% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.15 vs. ALGN: 14.68 )
Ranked among companies with meaningful PS Ratio only.
ALGN' s PS Ratio Range Over the Past 10 Years
Min: 1.31  Med: 5.27 Max: 18.44
Current: 14.68
1.31
18.44
Price-to-Free-Cash-Flow 96.32
ALGN's Price-to-Free-Cash-Flow is ranked lower than
89% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 26.44 vs. ALGN: 96.32 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ALGN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 11.18  Med: 24.54 Max: 120.9
Current: 96.32
11.18
120.9
Price-to-Operating-Cash-Flow 51.22
ALGN's Price-to-Operating-Cash-Flow is ranked lower than
84% of the 127 Companies
in the Global Medical Devices industry.

( Industry Median: 20.01 vs. ALGN: 51.22 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ALGN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.24  Med: 20.33 Max: 64.29
Current: 51.22
8.24
64.29
EV-to-EBIT 56.66
ALGN's EV-to-EBIT is ranked lower than
85% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 24.76 vs. ALGN: 56.66 )
Ranked among companies with meaningful EV-to-EBIT only.
ALGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -71.5  Med: 23.3 Max: 97.9
Current: 56.66
-71.5
97.9
EV-to-EBITDA 51.29
ALGN's EV-to-EBITDA is ranked lower than
89% of the 188 Companies
in the Global Medical Devices industry.

( Industry Median: 18.14 vs. ALGN: 51.29 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -269.2  Med: 20 Max: 65.7
Current: 51.29
-269.2
65.7
EV-to-Revenue 14.03
ALGN's EV-to-Revenue is ranked lower than
82% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 3.73 vs. ALGN: 14.03 )
Ranked among companies with meaningful EV-to-Revenue only.
ALGN' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.9  Med: 4.8 Max: 18
Current: 14.03
0.9
18
PEG Ratio 4.26
ALGN's PEG Ratio is ranked lower than
60% of the 77 Companies
in the Global Medical Devices industry.

( Industry Median: 2.53 vs. ALGN: 4.26 )
Ranked among companies with meaningful PEG Ratio only.
ALGN' s PEG Ratio Range Over the Past 10 Years
Min: 1.12  Med: 2.35 Max: 5.24
Current: 4.26
1.12
5.24
Shiller PE Ratio 194.44
ALGN's Shiller PE Ratio is ranked lower than
95% of the 58 Companies
in the Global Medical Devices industry.

( Industry Median: 49.95 vs. ALGN: 194.44 )
Ranked among companies with meaningful Shiller PE Ratio only.
ALGN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 75.39  Med: 108.62 Max: 680.5
Current: 194.44
75.39
680.5
Current Ratio 2.23
ALGN's Current Ratio is ranked lower than
56% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 2.71 vs. ALGN: 2.23 )
Ranked among companies with meaningful Current Ratio only.
ALGN' s Current Ratio Range Over the Past 10 Years
Min: 1.59  Med: 2.93 Max: 6.96
Current: 2.23
1.59
6.96
Quick Ratio 2.14
ALGN's Quick Ratio is ranked higher than
54% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. ALGN: 2.14 )
Ranked among companies with meaningful Quick Ratio only.
ALGN' s Quick Ratio Range Over the Past 10 Years
Min: 1.55  Med: 2.85 Max: 6.82
Current: 2.14
1.55
6.82
Days Inventory 31.70
ALGN's Days Inventory is ranked higher than
91% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 143.61 vs. ALGN: 31.70 )
Ranked among companies with meaningful Days Inventory only.
ALGN' s Days Inventory Range Over the Past 10 Years
Min: 9.28  Med: 29.95 Max: 32.75
Current: 31.7
9.28
32.75
Days Sales Outstanding 78.81
ALGN's Days Sales Outstanding is ranked lower than
62% of the 276 Companies
in the Global Medical Devices industry.

( Industry Median: 69.21 vs. ALGN: 78.81 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.69  Med: 64.13 Max: 83.63
Current: 78.81
61.69
83.63
Days Payable 41.34
ALGN's Days Payable is ranked lower than
70% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 58.34 vs. ALGN: 41.34 )
Ranked among companies with meaningful Days Payable only.
ALGN' s Days Payable Range Over the Past 10 Years
Min: 25.83  Med: 44.24 Max: 68.75
Current: 41.34
25.83
68.75

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.10
ALGN's 3-Year Average Share Buyback Ratio is ranked higher than
88% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: -5.70 vs. ALGN: 0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -139.2  Med: -3 Max: 0.5
Current: 0.1
-139.2
0.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1640.47
ALGN's Price-to-Net-Cash is ranked lower than
94% of the 104 Companies
in the Global Medical Devices industry.

( Industry Median: 14.24 vs. ALGN: 1640.47 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ALGN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.73  Med: 21.34 Max: 2790.33
Current: 1640.47
1.73
2790.33
Price-to-Net-Current-Asset-Value 44.46
ALGN's Price-to-Net-Current-Asset-Value is ranked lower than
89% of the 207 Companies
in the Global Medical Devices industry.

( Industry Median: 7.79 vs. ALGN: 44.46 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ALGN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.35  Med: 9.63 Max: 48.81
Current: 44.46
1.35
48.81
Price-to-Tangible-Book 22.07
ALGN's Price-to-Tangible-Book is ranked lower than
89% of the 276 Companies
in the Global Medical Devices industry.

( Industry Median: 4.50 vs. ALGN: 22.07 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ALGN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.91  Med: 6.51 Max: 24.24
Current: 22.07
0.91
24.24
Price-to-Intrinsic-Value-Projected-FCF 6.62
ALGN's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
80% of the 121 Companies
in the Global Medical Devices industry.

( Industry Median: 2.44 vs. ALGN: 6.62 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ALGN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.38  Med: 2.34 Max: 14.76
Current: 6.62
1.38
14.76
Price-to-Median-PS-Value 2.79
ALGN's Price-to-Median-PS-Value is ranked lower than
94% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. ALGN: 2.79 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALGN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.34  Med: 0.87 Max: 6.04
Current: 2.79
0.34
6.04
Price-to-Peter-Lynch-Fair-Value 3.99
ALGN's Price-to-Peter-Lynch-Fair-Value is ranked lower than
74% of the 47 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. ALGN: 3.99 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ALGN' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.57  Med: 2.21 Max: 14.72
Current: 3.99
0.57
14.72
Price-to-Graham-Number 9.22
ALGN's Price-to-Graham-Number is ranked lower than
95% of the 133 Companies
in the Global Medical Devices industry.

( Industry Median: 2.11 vs. ALGN: 9.22 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ALGN' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.86  Med: 3.36 Max: 17.76
Current: 9.22
0.86
17.76
Earnings Yield (Greenblatt) % 1.77
ALGN's Earnings Yield (Greenblatt) % is ranked higher than
56% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.74 vs. ALGN: 1.77 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALGN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -6.2  Med: 4 Max: 9.1
Current: 1.77
-6.2
9.1
Forward Rate of Return (Yacktman) % 20.79
ALGN's Forward Rate of Return (Yacktman) % is ranked higher than
86% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 6.60 vs. ALGN: 20.79 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ALGN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.4  Med: 3 Max: 23
Current: 20.79
0.4
23

More Statistics

Revenue (TTM) (Mil) $1,733.77
EPS (TTM) $ 3.60
Beta1.78
Volatility46.85%
52-Week Range $198.44 - 398.88
Shares Outstanding (Mil)80.32

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 1,979 2,543 3,115
EBIT (Mil $) 496 659 820
EBITDA (Mil $) 543 712 867
EPS ($) 5.00 6.46 7.94
EPS without NRI ($) 5.00 6.46 7.94
EPS Growth Rate
(Future 3Y To 5Y Estimate)
31.58%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}